Evidence map›Paper›PMID 42602228›Full record

ReviewFrontiers in transplantation2026

Chimerism practices across Canadian transplant centres: review of current standards and variations.

Matthew Gravina, Kylie Lepic, Brian Leber, Irwin Walker, Tobias Berg, Wilson Lam, Alejandro Garcia-Horton, Shreyash Dalmia, Daria Grafodatskaya, Darci T Butcher and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew GravinaDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Kylie LepicDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Brian LeberDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Irwin WalkerDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Tobias BergDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Wilson LamDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Alejandro Garcia-HortonDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Shreyash DalmiaDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Daria GrafodatskayaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Darci T ButcherDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Joseph Alexander AzizDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Michael RadfordDepartment of Oncology, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimerism analysis is used in hematopoietic stem cell transplantation (HSCT) to evaluate donor engraftment and assess underlying disease status. Practices vary greatly amongst Canadian transplant centres, and currently, there are no consensus guidelines for testing methodology, time points, cellular source and clinical interventions. Objectives: To review the current chimerism practice patterns for Canadian transplant centres and review current literature. Study design: We surveyed members of Cell Therapy and Transplant Canada (CTTC) via a web based application regarding chimerism practices nationwide with approximately half of all transplant centres responding. Results: The majority of centres used similar chimerism laboratory methodologies, though we identified key areas of heterogeneity across transplant centres, namely in the time points for testing and the cellular lineages evaluated. Implications and management of mixed donor chimerism also varied between centres resulting in variability of interventions. Conclusions: Review of current chimerism testing literature highlighted the improving sensitivities of novel testing methods available as well as testing specific cellular lineages to evaluate ongoing donor hematopoiesis. Our survey emphasizes the importance of advocating for a national standard in chimerism testing, and subsequent management based on chimerism results, to better inform clinical practice and to aid in development of prospective research.

Indexed as

allogeneic stem cell transplantCanadachimerismhematologynext generation sequencing (NGS)

Identifiers

PMID42602228
PMCPMC13473900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.